eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for Basal Cell Skin Cancer
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Radiation Therapy Compendium™ for Basal Cell Skin Cancer. These NCCN Guidelines® are currently available as Version 2.2024.
Link directly to the Updates section of the NCCN Guidelines: Basal Cell Skin Cancer
September 14, 2023 - Category correction for Version 1.2024
BCC-2
- Primary Treatment, Non-surgical modalities for tumors clinically and histologically consistent with superficial BCC (without dermal extension):
- Third bullet, Photodynamic therapy, porfimer sodium was revised from category 2A to category 2B.
Updates in Version 2.2024 of the NCCN Guidelines for Basal Cell Skin Cancer from Version 1.2024 include:
BCC-1
- Footnote g revised: Imaging modality and targeted area should be at the discretion of the treating team based on the suspected extent of disease (ie, local, regional, metastatic). Histologic confirmation is
oftensufficient to diagnose local recurrence, but MRI with and without contrast can be considered to assess extent of local disease. . .
BCC-2
- Primary Treatment, Non-surgical modalities for tumors clinically and histologically consistent with superficial BCC (without dermal extension), third bullet revised: Photodynamic therapy (eg, topical aminolevulinic acid [ALA], porfimer sodium [category 2B]) (Useful in Certain Circumstances).
BCC-C
- Second bullet revised: Surgical approaches often offer the most effective and efficient means for accomplishing cure, but considerations of function, cosmesis, and patient preference may lead to choosing RT/topical therapy/systemic therapy as primary treatment in order to achieve
satisfactoryoptimal overall results. - Fourth bullet revised: In patients with superficial basal cell skin cancer, non-surgical modalities
therapies such as topical imiquimod, topical 5-FU, photodynamic therapy (eg, ALA, porfimer sodium),a or cryotherapymay be considered. (See BCC-2)
BCC-E 1 of 2
- None added to Preferred Regimens for Locally Advanced Disease - Neoadjuvant, Locally Advanced Disease, Nodal Disease, and Metastatic Disease.
MS-1
- The Discussion section has been updated to reflect the changes in the algorithm.
Previous updates to the NCCN Guidelines for Basal Cell Skin Cancer can be found in the UPDATES section of the current version.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.